clinical trial · NCT03412747
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
UCB Biopharma SRL·phase3·completed·n = 478
Chronic Plaque PsoriasisModerate to Severe Plaque PsoriasisBimekizumabAdalimumabPlacebo
brief summary
This is a study to compare the efficacy of bimekizumab versus adalimumab in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).
started
Jan 26, 2018
primary completion
Feb 7, 2019
completion
Feb 26, 2020
last updated
Apr 15, 2026
official title
A Phase 3, Multicenter, Randomized, Double-Blind Study With an Active-Controlled Initial Treatment Period Followed by a Dose-Blind Maintenance Treatment Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol